Erstad, B. L., Erstad, B. L., Campbell, A. M., & Campbell, A. M. (2017). Tapering Regimens Following Medium to High Dose Extended Duration Corticosteroid Monotherapy in Adults with Rheumatic Disease: A Systematic Review. Pharmacotherapy, 37(6), e38-e70. doi:10.1002/phar.1964
Erstad, B., Patanwala, A. E., Duby, J., Waters, D., & Erstad, B. L. (2007). Opioid conversions in acute care. The Annals of pharmacotherapy, 41(2).
To discuss the historical basis and limitations of opioid conversion tables, review the relevant literature, and establish an evidence-based equianalgesic dose ratio (EDR) table for performing conversions in the acute care setting.
Murray, M. J., Cowen, J., DeBlock, H., Erstad, B., Gray Jr., A. W., Tescher, A. N., McGee, W. T., Prielipp, R. C., Susla, G., Jacobi, J., Nasraway Jr., S. A., & Lumb, P. D. (2002). Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Critical Care Medicine, 30(1), 142-156.
Gales, B. J., & Erstad, B. L. (1993). Adverse reactions to human serum albumin. Annals of Pharmacotherapy, 27(1), 87-94.
PMID: 8431628;Abstract:
OBJECTIVE: To describe the adverse effects associated with human serum albumin (HSA) administration. DATA SOURCES: A MEDLINE search and bibliography scanning were used to identify pertinent review articles, clinical studies, and case reports. STUDY SELECTION: Emphasis was placed on reporting the results of human studies with the primary objective of investigating adverse effects attributable to HSA administration. Clinical trials that reported the occurrence of adverse effects possibly associated with HSA were also reviewed. Animal data were included where pertinent. DATA EXTRACTION: Although isolated case reports were reviewed, data were primarily extracted from human studies involving large series of patients or studies that were randomized and prospective in nature. DATA SYNTHESIS: Alterations in coagulation, renal, cardiovascular, and pulmonary functions were identified as potential adverse effects following the administration of HSA. Occurrences of hypersensitivity reactions, trace metal loading, and serum amino acid alterations associated with these infusions were also noted and are described here. Pulmonary and cardiovascular systems appear to be particularly prone to complications from excessive HSA administration. Adverse effects such as HSA- induced hypersensitivity reactions may be severe, but occur infrequently. CONCLUSIONS: Controlled studies involving large numbers of patients are not currently available for an accurate assessment of the incidence of adverse effects attributable to HSA administration. Many of the reported reactions appear to be extensions of albumin's pharmacologic activities and would be expected to worsen following large doses of HSA.
Radosevich, J. J., Patanwala, A. E., & Erstad, B. L. (2013). Emerging pharmacological agents to improve survival from traumatic brain injury. Brain Injury, 27(13-14), 1492-1499.
PMID: 24205899;Abstract:
Objective: To review emerging pharmacological agents for the treatment of traumatic brain injury with regard to survival outcomes and provide recommendations regarding their use. Methods: An Ovid MEDLINE (up to May 2013) and the Cochrane Central Register of Controlled Trials (up to May 2013) search was conducted to identify emerging pharmacological therapies for the treatment of traumatic brain injury. The search was limited to English language and humans. Pharmacological agents that were evaluated with respect to survival as an outcome were included. Main results: Based on the search, the investigators identified the following new therapies: beta-receptor antagonists, erythropoiesis stimulating agents, hydroxymethylglutaryl-CoA reductase inhibitors (statins) and progesterone. With the exception of progesterone, which was studied in several small, randomized, controlled trials, the remaining agents were primarily studied in observational retrospective cohorts. For each of the agents identified, a potential increase in survival was noted. Conclusions: Emerging pharmacological agents represent promising treatment options for traumatic brain injury to improve survival. Most of these agents are commercially available for other indications. However, limitations in study design, sample size, duration of treatment, timing of treatment and inclusion of heterogeneous patient populations make it difficult to draw definitive conclusions from the literature. © 2013 Informa UK Ltd.
